Sort by:

• Highly Influential Citations
• Citations
• Acceleration
• Velocity
• Recency

Learn More

Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.

• Michael R. Zalutsky, Abraham Boskovitz, +8 authors Darell D Bigner
• Nuclear medicine and biology
• 2012

INTRODUCTION Malignant glioma remains a significant therapeutic challenge, and immunotherapeutics might be a beneficial approach for these patients. A monoclonal antibody (MAb) specific for multiple… (More)

MRP3: a molecular target for human glioblastoma multiforme immunotherapy.

• C. - H. Kuan, Kenji Wakiya, +8 authors Darell D Bigner
• BMC Cancer
• 2010

Glioblastoma multiforme (GBM) is refractory to conventional therapies. To overcome the problem of heterogeneity, more brain tumor markers are required for prognosis and targeted therapy. We have… (More)

Distress persists in long-term brain tumor survivors with glioblastoma multiforme.

• Stephen Thomas Keir, Margaret M Farland, Eric S. Lipp, Henry S. Friedman
• Journal of cancer survivorship : research and…
• 2008

INTRODUCTION Glioblastoma multiforme (GBM) is the most common and aggressive type of primary brain tumor. The prognosis for GBM patients is extremely poor with an estimated median survival of 12… (More)

Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma

• David A Reardon, Andrew David Norden, +12 authors Henry S. Friedman
• Journal of Neuro-Oncology
• 2011

We prospectively evaluated the efficacy and safety of imatinib plus hydroxyurea in patients with progressive/recurrent meningioma. A total of 21 patients with progressive/recurrent meningioma were… (More)

Prognostic Value of Medulloblastoma Extent of Resection After Accounting for Molecular Subgroup: An Integrated Clinical and Molecular Analysis

• Eric M. Thompson, Thomas Hielscher, +104 authors Michael D. Taylor
• 2016

Background—Incomplete surgical resection of medulloblastoma is controversially considered a marker of high-risk disease; driving aggressive surgical resections, “second-look” surgeries, and/or… (More)

Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.

• David A Reardon, Annick Desjardins, +10 authors Henry S. Friedman
• Cancer
• 2012

BACKGROUND We evaluated the efficacy of imatinib plus hydroxyurea in patients with progressive/recurrent low-grade glioma. METHODS A total of 64 patients with recurrent/progressive low-grade glioma… (More)

Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis.

• Vijay Ramaswamy, Thomas Hielscher, +112 authors Michael D. Taylor
• Journal of clinical oncology : official journal…
• 2016

PURPOSE Posterior fossa ependymoma comprises two distinct molecular variants termed EPN_PFA and EPN_PFB that have a distinct biology and natural history. The therapeutic value of cytoreductive… (More)

Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients

• David A Reardon, James E. Herndon, +11 authors James J. Vredenburgh
• Journal of Neuro-Oncology
• 2011

Although outcome following bevacizumab among recurrent grade IV malignant glioma patients is documented as poor by several analyses, outcome for recurrent grade III patients following bevacizumab… (More)

Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.

• Katherine B. Peters, Emil Lou, +7 authors James J. Vredenburgh
• The oncologist
• 2015

LESSONS LEARNED Trials focusing on unresectable multifocal glioblastoma are needed because of the extremely poor prognosis and challenges in receiving standard therapy, such as concurrent radiation… (More)

Consultative issues in surgical neuropathology: a retrospective review of the rationale for submitting cases for expert review.

• Eric S. Lipp, Alysha C Clark, Roger E McLendon
• American journal of clinical pathology
• 2015

OBJECTIVES Second opinions on neuropathology cases are sought for a variety of reasons. We investigated the rationales for seeking expert neuropathologic review. METHODS A retrospective review was… (More)

• ‹
• 1
• 2
• ›